Table 5 Association between goshajinkigan preventive administration and CIPN severity

Age (years)

70 (57–79)^c

66 (37–79)^c

0.535^a

Gender (male/female)

16 / 7

55 / 27

0.822^b

nabPTX cumulative dosage (mg)

1112 (400–7364)^c

1589 (360–7226)^c

0.139^a

Pretreatment history of oxaliplatin, n (%)

8 (35%)

35 (43%)

0.496^b

Oxaliplatin cumulative dosage (mg)

941 (510–4399)^c

1040 (100–4405)^c

0.679^a

History of CIPN at the initiation of GnP, n (%)

9 (39%)

54 (65%)

0.371^b

Pretreatment history of pregabalin, n (%)

4 (17%)

4 (49%)

0.068^b

CIPN (−), n (%)

4 (17%)

29 (35%)

0.716^a

  Grade 1, n (%)

12 (52%)

29 (35%)

  Grade 2, n (%)

7 (30%)

17 (21%)

  Grade 3, n (%)

0 (0%)

7 (9%)